Company Overview and News

 
Sri Lankan shares fall to 3-mth low ahead of monetary policy

2016-11-01 bizenglish.adaderana.lk
Reuters – Sri Lankan shares ended Monday weaker at a three-month low in thin trade ahead of a monetary policy announcement by the central bank, as the prime minister’s plan for improving the investment climate failed to cheer the market.

 
Silver for Guardian Acuity Money Market Fund from CFA Institute

2016-08-08 bizenglish.adaderana.lk
The Guardian Acuity Money Market Fund won silver at the recently concluded CFA Awards night in the category of mutual funds. This was the first time that the CFA Institute recognized the mutual funds industry for their performance. The evaluation committee had laid out stringent criteria such as disclosure policies, risk management and compliance, investment process, trading practices and last but not the least formalizing practices that put the client first.

 
Sri Lanka’s First Dual Return Investment Plan From Guardian Acuity And Alliance Finance

2016-07-29 bizenglish.adaderana.lk
An Opportunity To Secure A Regular Income While Growing Your Capital “Alpha plus”, Sri Lanka’s first dual return investment plan is now available to investors as a result of a partnership between Alliance Finance PLC and Guardian Acuity Asset Management (GAAM), a leading Unit Trust Management Company which is part of Carson Cumberbatch PLC, HNB and DFCC banks.

 
Guardian Acuity launches Sri Lanka’s first dual return investment plan

2016-07-29 lankabusinessonline
“Alpha plus”, Sri Lanka’s first dual return investment plan is now available to investors as a result of a partnership between Alliance Finance PLC and Guardian Acuity Asset Management (GAAM), a leading Unit Trust Management Company which is part of Carson Cumberbatch PLC, HNB and DFCC banks.

 
Guardian Acuity Money Market Fund offers 11.37-pct annualized return

2016-06-22 lankabusinessonline
The Guardian Acuity Money Market fund which is more than four years old has returned 48.44% to its investors. This is an annualized return of 11.37%. The fund invests in government securities, fixed deposits and commercial papers and provides for easy withdrawals with no penalties for withdrawals.

 
Guardian Acuity Money Market Funds offers option to take advantage of current interest rates outlook

2016-06-22 bizenglish.adaderana.lk
The Guardian Acuity Money Market fund which is more than four years old has returned 48.44% to its investors. This is an annualized return of 11.37%. The fund invests in government securities, fixed deposits and commercial papers and provides for easy withdrawals with no penalties for withdrawals.

 
Guardian Capital Partners to invest in private equity projects in Sri Lanka

2016-05-04 lankabusinessonline
May 04, 2016 (LBO) – Guardian Capital Partners, a part of the listed Ceylon Guardian Investment Trust Group has entered into a joint venture agreement with Small Enterprise Assistance Funds (SEAF) in US to carry on a fund management business to manage and invest in private equity projects in Sri Lanka.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...